IMEXF (Imagin Medical) EBITDA per Share: $-0.23 (TTM As of Jun. 2023)


What is Imagin Medical EBITDA per Share?

Imagin Medical IMEXF -99.00% EBITDA per Share is $-0.23 as of Jun. 2023.

Imagin Medical's EBITDA per Share for the three months ended in Jun. 2023 was $0.16. Its EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.23.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Imagin Medical's EBITDA per Share or its related term are showing as below:

IMEXF's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Imagin Medical's EBITDA for the three months ended in Jun. 2023 was $1.69 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Imagin Medical  (OTCPK:IMEXF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Imagin Medical EBITDA per Share Related Terms


Imagin Medical EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Imagin Medical's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagin Medical EBITDA per Share Chart

Imagin Medical Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.13 -0.48 -0.40 -1.00 -0.18

Imagin Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 -0.34 0.00 -0.06 0.16

Imagin Medical EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Imagin Medical's EBITDA per Share for the fiscal year that ended in Sep. 2022 is calculated as

EBITDA per Share(A: Sep. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=-1.827/9.998
=-0.18

Imagin Medical's EBITDA per Share for the quarter that ended in Jun. 2023 is calculated as

EBITDA per Share(Q: Jun. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=1.694/10.830
=0.16

EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $-0.23 mean?
Imagin Medical (IMEXF) has a EBITDA per Share of $-0.23 as of Jun. 2023. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Imagin Medical and its competitors.
Is Imagin Medical's EBITDA per Share too high?
Imagin Medical's current EBITDA per Share is $-0.23.
How does Imagin Medical's EBITDA per Share compare to ABT and SYK?
Imagin Medical's EBITDA per Share of $-0.23 can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA per Share is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Devices & Instruments company?
The median EBITDA per Share among Medical Devices & Instruments companies is 7.90, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Imagin Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA per Share is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagin Medical's current EBITDA per Share is $-0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagin Medical stock overvalued right now?
Imagin Medical (IMEXF) has a current EBITDA per Share of $-0.23. The current EBITDA per Share is $-0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Imagin Medical (IMEXF), the current EBITDA per Share is $-0.23 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagin Medical Business Description

Address 890 West Pender Street, Suite 600, Vancouver, BC, CAN, V6C 1J9
Imagin Medical Inc is a Urologic Oncology company developing technologies to visualize and treat urologic cancers, including bladder and prostate cancer, through minimally invasive surgery. The company's first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer, helping to improve the surgical management of this disease. Imagin's follow-on product, the enCAGE Coil is a device with 510(k) clearance for soft tissue ablation. Imagin intends to refine the disposable bipolar radio frequency-based probe for use in the treatment of prostate cancer and benign prostate hypoplasia (BPH) and submit appropriate FDA premarket applications for the new indications.